Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients
Recruitment status was Recruiting
The purpose of this study is to determine whether on-line hemodiafiltration ameliorate the endothelial dysfunction compared with the low flux hemodialysis in end stage renal disease patients on maintenance hemodialysis.
End Stage Renal Disease
Procedure: On-line hemodiafiltration
Procedure: Low flux hemodialysis
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients|
- endothelial dysfunction measured by flow-mediated vasodilation [ Time Frame: 4 months ]
|Study Start Date:||April 2007|
|Estimated Study Completion Date:||March 2008|
|Experimental: O||Procedure: On-line hemodiafiltration|
|Active Comparator: L||Procedure: Low flux hemodialysis|
- On-line hemodiafiltration(OL-HDF) is a technique that combines diffusion with convection in which the large substitution fluid is produced directly from the dialysate. It offers many advantages aside from its safe inflammatory profile, which is attributable to the use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an improved convective clearance, significantly increased removal of large or protein-bound uremic retention solutes can be achieved, with a potential benefit on cardiovascular morbidity and mortality.
- Endothelial dysfunction, almost universal in end stage renal disease, is important risk factor for cardiovascular events, and can be evaluated by brachial artery endothelium-dependent vasodilation (flow-mediated dilation) to reactive hyperemia following 5 min of forearm ischemia.
- The stable HD patients will receive 8-week treatment on OL-HDF or conventional low flux HD and then crossed over to opposite treatment arm. The FMD will be measured by one sonographer, and at the same time whole blood and serum will be sampled and stored for further analysis. The timepoint for measurement is 4-week interval after baseline evaluation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532597
|Contact: Young-Hwan Hwang, M.D.||email@example.com|
|Contact: Su-Ah Sung, M.D., PhD.||firstname.lastname@example.org|
|Korea, Republic of|
|Eulji General Hospital||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Young-Hwan Hwang, M.D. 82-2-970-8457 email@example.com|
|Contact: Su-Ah Sung, M.D.,PhD. 82-2-970-8205 firstname.lastname@example.org|
|Study Chair:||SuAh Sung, M.D.,PhD.||Department of Internal Medicine, College of Medicine, Eulji University|